5 Key Takeaways

• 1

  A blood test measuring amyloid beta aggregation distinguished Alzheimer’s disease and mild cognitive impairment from normal cognition and other dementias.

• 2

  The study involved 549 patients, including those with Alzheimer’s dementia, mild cognitive impairment, and various non-Alzheimer’s dementias.

• 3

  The test utilized protein misfolding cyclic amplification to detect misfolded amyloid beta in plasma, with results available within 24 hours.

• 4

  In the validation group, amyloid beta seeding activity was significantly higher in Alzheimer’s patients compared to cognitively unimpaired individuals.

• 5

  The assay demonstrated high diagnostic performance, with area under the curve values of 0.93 for Alzheimer’s disease versus normal cognition.